Monday, August 31, 2020 2:27:40 PM
Completely doomed company. Nobody touching it! More vol pre-market than trading.
LOL abuser
Someone who uses lol not only too much in a conversation, but is most likely NOT laughing out loud at what was previously said. Not only is this person an abuser of an already retarded term, but they are a liar.
Recent AKTX News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2026 08:40:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 08:30:23 PM
- This Emerging Biotech Wave Could Create the Next Monster Healthcare Winners • GlobeNewswire Inc. • 05/22/2026 01:42:40 PM
- Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models • GlobeNewswire Inc. • 05/21/2026 09:01:00 PM
- Akari Therapeutics Announces $5.5 Million Private Placement Offering • GlobeNewswire Inc. • 05/21/2026 12:30:00 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 05/21/2026 12:15:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/19/2026 09:00:50 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/18/2026 09:15:18 PM
- Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase • GlobeNewswire Inc. • 05/18/2026 01:05:00 PM
- Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets • GlobeNewswire Inc. • 05/12/2026 12:33:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/08/2026 09:08:03 PM
- Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload • GlobeNewswire Inc. • 04/27/2026 12:35:00 PM
- Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors • GlobeNewswire Inc. • 04/21/2026 01:00:00 PM
- Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing • GlobeNewswire Inc. • 04/20/2026 12:35:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/16/2026 04:15:07 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/10/2026 08:15:02 PM
- Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC • GlobeNewswire Inc. • 04/09/2026 12:50:00 PM
- Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing • GlobeNewswire Inc. • 04/06/2026 12:45:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:39:37 PM
- Akari Therapeutics to present ADC research at AACR Annual Meeting 2026 • IH Market News • 03/18/2026 03:02:39 PM
- Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 • GlobeNewswire Inc. • 03/18/2026 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 09:07:26 PM
- Akari Therapeutics Announces ADS Ratio Change • GlobeNewswire Inc. • 03/17/2026 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 09:00:03 PM
- Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala • GlobeNewswire Inc. • 03/13/2026 01:15:00 PM
